ES2544874T3 - Dispositivo de administración de insulina - Google Patents
Dispositivo de administración de insulina Download PDFInfo
- Publication number
- ES2544874T3 ES2544874T3 ES11833366.5T ES11833366T ES2544874T3 ES 2544874 T3 ES2544874 T3 ES 2544874T3 ES 11833366 T ES11833366 T ES 11833366T ES 2544874 T3 ES2544874 T3 ES 2544874T3
- Authority
- ES
- Spain
- Prior art keywords
- controller
- zone
- blood glucose
- insulin delivery
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
Abstract
Un dispositivo de administración de insulina que comprende un sistema de sensor para la medición de la glucosa, un controlador y un sistema de administración de insulina, en que el sistema de sensor de glucosa genera una señal de sensor representativa de los niveles de glucosa en sangre y proporciona las señales del sensor al controlador, en que el controlador recibe la señal del sensor y genera comandos que se comunican al sistema de administración de insulina, en que el sistema de administración de insulina recibe los comandos e infunde la insulina en el cuerpo en respuesta a los comandos, caracterizado porque el controlador comprende un algoritmo de control predictivo de modelo multi-zona (MPC) basado en cuatro distribuciones regionales de glucemia, que comprende zonas de hipoglucemia, normoglucemia, glucemia elevada e hiperglucemia, en que en la zona de hiperglucemia, es decir, una concentración de glucosa en sangre de G > 180 mg / dL, las acciones de control se limitan a evitar la sobredosis, en que en la zona de glucemia elevada, es decir 140 < G < 180 mg / dL se implementan la mayor parte de las acciones de control, en que en la zona de normoglucemia, es decir 80 < G < 140 mg / dL, el controlador es quiescente a la desviación en las mediciones de glucosa, y en que en la zona de hipoglucemia, es decir G < 80 mg / dL, al controlador se le permite una respuesta rápida a una hipoglucemia potencial.
Description
E11833366
07-08-2015
donde PH es el horizonte de predicción de ocho horas y veinte minutos. La optimización se lleva a cabo bajo las siguientes limitaciones:
- 1.
- Para la estabilidad y el anti-aliasing, las raíces del polinomio característico,
se encuentran todas dentro del lado derecho (RHS) de la unidad de círculo, donde de insulina y de glucosa tal como se describe en (1).
- 2. Requisito de ganancia negativa de insulina,
imagen8 , dóndeimagen9 son los regresores de glucosa e insulina, respectivamente, tal como se describe en (1).
- 3.
- Requisito de ganancia positiva de comida,
dónde imagen12 son los regresores de glucosa y de la comida, respectivamente, tal como se describe en (1).
4. Ninguna respuesta inversa en la insulina y la comida. Esto se consigue limitando todos los βi ≥ 0 y 15 todos los χi ≤0.
El resultado de la optimización se representa en la Fig. 1 (b) y describe un modelo que capta el comportamiento general de la población de 10 sujetos.
20 El MPC optimiza cada muestra de control con una función de coste que incluye P instantes de proceso futuro, conocida como horizonte de predicción, y CM futuro de M, el horizonte de control. En cada muestra, la optimización se repite utilizando los datos de proceso actualizados. Sin embargo, sólo el primer CM de cada secuencia optimizada se implementa en el proceso. Las limitaciones del proceso de entrada se incluyen para que la solución óptima impida la futura violación de la limitación.
25 Guiada por la práctica médica, la concentración de glucosa en sangre se puede dividir en cuatro zonas: Zona 1, hiperglucemia, BG> 180 mg / dL; zona 2, glucemia cerca de la normalidad, 140 <BG <180 mg / dl; zona 3, normoglucemia, 80 <BG <140 mg / dL, y zona 4, peligro inminente de hipoglucemia, BG <80 mg / dL. Estas zonas se incluyen en la función de costes utilizada en el MPC Multi-Zona que se describe
30 mediante la siguiente ecuación:
donde Ḡ’k es una función binaria que produce los valores del límite superior de la zona de la normoglucemia (140 mg / dL) cuando Ḡ’k > 140 mg / dL, y proporciona de los valores del límite inferior de
35 la zona de normoglucemia (80 mg / dL) cuando Ḡ’k <80 mg / dL. Qk y Rk son pesos de optimización dependientes de la concentración de glucosa en sangre predichos, tal como se enumeran en la Tabla 1. P y M son el horizonte de predicción y el horizonte de control de salida, respectivamente.
El MPC Multi-Zona predice P fases en cada muestra de control. Qk y Rk cambian los valores según las
40 predicciones. Si 80 ≤ Ḡ’k <140, entonces Qk se pone a cero. Si Ḡ’k > 180 mg / dL durante al menos una sola predicción, entonces Qk y Rk se cambian a Qk = 1 y Rk =5000. De lo contrario, Rk = 0.5 para todas las predicciones y Qk cambia de acuerdo con cada valor de Ḡ’k.
45
9
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39239910P | 2010-10-12 | 2010-10-12 | |
US392399P | 2010-10-12 | ||
PCT/US2011/056022 WO2012051344A2 (en) | 2010-10-12 | 2011-10-12 | Maintaining multiple defined physiological zones using model predictive control |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2544874T3 true ES2544874T3 (es) | 2015-09-04 |
Family
ID=45938960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11833366.5T Active ES2544874T3 (es) | 2010-10-12 | 2011-10-12 | Dispositivo de administración de insulina |
Country Status (8)
Country | Link |
---|---|
US (1) | US9700708B2 (es) |
EP (1) | EP2628115B1 (es) |
JP (1) | JP6062859B2 (es) |
CA (1) | CA2816388C (es) |
DK (1) | DK2628115T3 (es) |
ES (1) | ES2544874T3 (es) |
HK (1) | HK1182496A1 (es) |
WO (1) | WO2012051344A2 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
US9757510B2 (en) | 2012-06-29 | 2017-09-12 | Animas Corporation | Method and system to handle manual boluses or meal events for closed-loop controllers |
US9486578B2 (en) * | 2012-12-07 | 2016-11-08 | Animas Corporation | Method and system for tuning a closed-loop controller for an artificial pancreas |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
AU2014205123B2 (en) * | 2013-01-14 | 2018-08-16 | The Regents Of University Of California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type 1 diabetes applications |
US9795737B2 (en) | 2013-03-15 | 2017-10-24 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
EP2973095B1 (en) | 2013-03-15 | 2018-05-09 | Animas Corporation | Insulin time-action model |
US9517306B2 (en) | 2013-03-15 | 2016-12-13 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
US9474855B2 (en) | 2013-10-04 | 2016-10-25 | Animas Corporation | Method and system for controlling a tuning factor due to sensor replacement for closed-loop controller in an artificial pancreas |
US9861747B2 (en) | 2013-12-05 | 2018-01-09 | Lifescan, Inc. | Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing |
GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
CN106714874B (zh) * | 2014-08-06 | 2019-10-08 | 加利福尼亚大学董事会 | 用于控制应用的滚动时域状态初始化器 |
EP4400130A3 (en) | 2015-02-18 | 2024-10-16 | Insulet Corporation | Fluid delivery and infusion devices |
EP3374905A1 (en) | 2016-01-13 | 2018-09-19 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
WO2017123703A2 (en) | 2016-01-14 | 2017-07-20 | Bigfoot Biomedical, Inc. | Occlusion resolution in medication delivery devices, systems, and methods |
EP3443998A1 (en) * | 2016-01-14 | 2019-02-20 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
FR3047098B1 (fr) * | 2016-01-21 | 2018-05-25 | Voluntis | Gestion de l'equilibre glycemique d'un patient diabetique |
BR112018015910A2 (pt) * | 2016-02-05 | 2018-12-26 | Animas Corporation | ferramenta de visualização e análise para um sistema de liberação de fármacos |
EP3515535A1 (en) | 2016-09-23 | 2019-07-31 | Insulet Corporation | Fluid delivery device with sensor |
CA3037432A1 (en) | 2016-12-12 | 2018-06-21 | Bigfoot Biomedical, Inc. | Alarms and alerts for medication delivery devices and related systems and methods |
US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
EP3568859A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
US10758675B2 (en) | 2017-01-13 | 2020-09-01 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10500334B2 (en) | 2017-01-13 | 2019-12-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10881792B2 (en) | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
EP3568860A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
US11497851B2 (en) | 2017-03-31 | 2022-11-15 | Lifescan Ip Holdings, Llc | Maintaining maximum dosing limits for closed loop insulin management systems |
US10729849B2 (en) | 2017-04-07 | 2020-08-04 | LifeSpan IP Holdings, LLC | Insulin-on-board accounting in an artificial pancreas system |
US11147920B2 (en) | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
ES2903174T3 (es) | 2017-05-05 | 2022-03-31 | Lilly Co Eli | Control de bucle cerrado de glucosa fisiológica |
EP3438858A1 (en) | 2017-08-02 | 2019-02-06 | Diabeloop | Closed-loop blood glucose control systems and methods |
WO2019125932A1 (en) | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Closed loop control of physiological glucose |
JP6938363B2 (ja) * | 2017-12-27 | 2021-09-22 | オムロンヘルスケア株式会社 | 情報処理装置、生体情報測定装置、方法及びプログラム |
USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
US11158413B2 (en) * | 2018-04-23 | 2021-10-26 | Medtronic Minimed, Inc. | Personalized closed loop medication delivery system that utilizes a digital twin of the patient |
AU2019263490A1 (en) | 2018-05-04 | 2020-11-26 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
AU2019288473A1 (en) | 2018-06-22 | 2020-12-10 | Ypsomed Ag | Insulin and pramlintide delivery systems, methods, and devices |
US11628251B2 (en) | 2018-09-28 | 2023-04-18 | Insulet Corporation | Activity mode for artificial pancreas system |
US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
USD920343S1 (en) | 2019-01-09 | 2021-05-25 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
US11986629B2 (en) * | 2019-06-11 | 2024-05-21 | Medtronic Minimed, Inc. | Personalized closed loop optimization systems and methods |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
EP4069082B1 (en) | 2019-12-06 | 2024-06-05 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
JP7512395B2 (ja) | 2020-01-06 | 2024-07-08 | インスレット コーポレイション | 持続する残差に基づく食事および/または運動行為の予測 |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
US12115351B2 (en) | 2020-09-30 | 2024-10-15 | Insulet Corporation | Secure wireless communications between a glucose monitor and other devices |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
EP4409581A1 (en) | 2021-09-27 | 2024-08-07 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
US12097355B2 (en) | 2023-01-06 | 2024-09-24 | Insulet Corporation | Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3251224B2 (ja) * | 1998-02-26 | 2002-01-28 | 勲 長澤 | 病棟情報システム |
US8423113B2 (en) * | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) * | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8369919B2 (en) * | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
JP5037496B2 (ja) * | 2005-05-13 | 2012-09-26 | トラスティーズ オブ ボストン ユニバーシティ | 1型糖尿病用の完全自動制御システム |
US9392969B2 (en) * | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8721584B2 (en) * | 2006-11-02 | 2014-05-13 | The University Of North Carolina At Chapel Hill | Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient |
US20080154513A1 (en) * | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
CN101663059A (zh) * | 2007-03-19 | 2010-03-03 | 梅丁格有限公司 | 药物输送设备中选择单次剂量的用户接口 |
US8221345B2 (en) * | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
EP2276405A4 (en) * | 2008-05-12 | 2013-10-09 | Us Dept Veterans Affairs | AUTOMATED SYSTEM AND METHOD FOR DIABETES CONTROL |
US9317657B2 (en) * | 2008-11-26 | 2016-04-19 | University Of Virginia Patent Foundation | Method, system, and computer program product for tracking of blood glucose variability in diabetes |
WO2010099313A1 (en) * | 2009-02-25 | 2010-09-02 | University Of Virginia Patent Foundation | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
-
2011
- 2011-10-12 CA CA2816388A patent/CA2816388C/en active Active
- 2011-10-12 ES ES11833366.5T patent/ES2544874T3/es active Active
- 2011-10-12 WO PCT/US2011/056022 patent/WO2012051344A2/en active Application Filing
- 2011-10-12 EP EP11833366.5A patent/EP2628115B1/en active Active
- 2011-10-12 DK DK11833366.5T patent/DK2628115T3/en active
- 2011-10-12 JP JP2013533983A patent/JP6062859B2/ja active Active
-
2013
- 2013-04-02 US US13/854,963 patent/US9700708B2/en active Active
- 2013-08-22 HK HK13109833.7A patent/HK1182496A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK2628115T3 (en) | 2015-08-24 |
HK1182496A1 (en) | 2013-11-29 |
EP2628115B1 (en) | 2015-06-03 |
CA2816388A1 (en) | 2012-04-19 |
WO2012051344A2 (en) | 2012-04-19 |
JP6062859B2 (ja) | 2017-01-18 |
US9700708B2 (en) | 2017-07-11 |
EP2628115A2 (en) | 2013-08-21 |
CA2816388C (en) | 2016-12-06 |
EP2628115A4 (en) | 2014-04-23 |
US20130231642A1 (en) | 2013-09-05 |
JP2013542011A (ja) | 2013-11-21 |
WO2012051344A3 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2544874T3 (es) | Dispositivo de administración de insulina | |
US11690577B2 (en) | Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered | |
CN111246898B (zh) | 自动确定和输送校正推注的流体输注系统 | |
US10940266B2 (en) | Control unit for infusion pump units, including a controlled intervention unit | |
US11278668B2 (en) | Analyte sensor and medicant delivery data evaluation and error reduction apparatus and methods | |
US11883208B2 (en) | Machine learning-based system for estimating glucose values based on blood glucose measurements and contextual activity data | |
US10517535B2 (en) | Method for controlling wearable device and wearable device | |
KR102407564B1 (ko) | 생체 정보를 판단하는 전자 장치 및 이의 동작 방법 | |
ES2973033T3 (es) | Sensor implantable | |
US20190008461A1 (en) | Analyte sensor data evaluation and error reduction apparatus and methods | |
US20230158235A1 (en) | Alert management based on sleeping status | |
CA2987429A1 (en) | Wireless analyte monitoring | |
US10357180B2 (en) | Health monitoring system | |
JP6224505B2 (ja) | 電源回路、電源システム、および携帯端末装置 | |
US10028686B2 (en) | Methods for generating hybrid analyte level output, and devices and systems related thereto | |
EP4262960A1 (en) | Wireless communication and power conservation for implantable monitors | |
US20220379029A1 (en) | Threshold based automatic glucose control response | |
Ata et al. | Model based control of artificial pancreas under meal disturbances | |
US12016684B2 (en) | Environmental detection and/or temperature compensation in an analyte monitoring system | |
US20230000401A1 (en) | Methods and systems for reducing difference between calculated and measured analyte levels | |
Tejavibulya | Development of a Skin Patch for Continuous Glucose Monitoring | |
KR20170082919A (ko) | 수면 시간을 이동하는 전자 장치 및 그 제어 방법 | |
De Micheli et al. | Lab-on-a-chip implants: a mini laboratory under the skin | |
Kolodkin et al. | Silicon Human: oxidative stress model for aging, Parkinson's disease and precision therapies |